title: Baseline cyst formation after luteal phase gonadotropin-releasing hormone agonist administration is linked to poor in vitro fertilization outcome.
abstract: OBJECTIVE
  To investigate the prognostic significance of baseline ovarian cysts after luteal phase GnRH agonist (GnRH-a) administration for IVF-ET.
  
  
  METHODS
  All nondonor IVF-ET cycles in one program in which luteal phase GnRH-a was administered between July 1993 and January 1994 were assessed for the formation of baseline ovarian cysts defined as a mean diameter > or = 15 mm. Outcome data from the IVF cycles were compared between patients with and without baseline ovarian cysts.
  
  
  RESULTS
  Of 78 IVF cycles, baseline cysts > or = 15 mm were noted in 26 cycles. Cycles in which cysts were formed were associated with significantly older patients with significantly higher baseline FSH values. Cycles in which cysts were present demonstrated fewer follicles, retrieved oocytes, and embryos. Cyst cycles also demonstrated a lower peak E2 level, implantation rate, and clinical pregnancy rate (PR) per initiated cycle (7.7% versus 32.7%). Cyst cycles also demonstrated a higher cancellation rate. Logistic regression modeling, accounting for age, confirmed significantly lower clinical PRs in cycles with a baseline cyst.
  
  
  CONCLUSIONS
  Baseline cyst formation after luteal phase GnRH-a administration is both a marker for poor responders and a reliable predictor of poor stimulation and low PRs in a given IVF-ET cycle.
authors.affiliation: Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Keltz
authors.forename: E E
authors.initials: EE
authors.lastname: Jones
authors.forename: A J
authors.initials: AJ
authors.lastname: Duleba
authors.forename: T
authors.initials: T
authors.lastname: Polcz
authors.forename: K
authors.initials: K
authors.lastname: Kennedy
authors.forename: D L
authors.initials: DL
authors.lastname: Olive
mesh_terms: D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D010064:Embryo Implantation; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage* / Q000627:therapeutic use; D008183:Luteal Phase; D010048:Ovarian Cysts / Q000000981:diagnostic imaging / Q000503:physiopathology*; D011247:Pregnancy; D011256:Pregnancy Outcome; D012044:Regression Analysis; D014463:Ultrasonography
chemical_list: D006063:Chorionic Gonadotropin; D004958:Estradiol; D016729:Leuprolide